Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Data Add To Strengthening Efficacy Case For Takeda Dengue Vaccine

Executive Summary

Newly published details of interim clinical data for Takeda's candidate vaccine for dengue show activity across all serotypes that seems to bode well for an ongoing Phase III trial with the potential rival to the only currently available vaccine, Sanofi's Dengvaxia.

You may also be interested in...



Sanofi's Dengue Vaccine Health Warning Seen Hitting Product's Sales

The French drug manufacturer admits the world’s first dengue vaccine may be harmful when administered to individuals not previously infected with the disease.

Takeda's Dengue Vaccine Still Promising, But Could Be A Niche Market

Long-term Phase II data have backed Takeda's drive to study its dengue vaccine in Phase III, but to grow the market the company may have to reverse the reluctance of countries to fund public vaccination campaigns.

Biological E Taps Takeda Tech For Affordable Combo Vaccines

Takeda is to transfer selected vaccine technologies to an Indian manufacturer to enable the production of affordable combination vaccines for lower income countries, although likely volumes and prices remain unclear for now.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel